Restoring Regulatory T Cells in Type 1 Diabetes

Spence, Allyson L.; Tang, Qizhi

doi:10.1007/s11892-016-0807-6

Cited by 32 publications

(35 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other mutations associated with Treg cell dysfunction are in loci, such as CD25 and cytotoxic T lymphocyte-associated antigen 4, which have been linked to autoimmunity risk in genome-wide association studies. 62 In the NOD mouse model, Treg cells do not control pancreatic islet destruction because of a survival disadvantage secondary to the paucity of IL-2 in chronically inflamed islets. 63 Single infusion ex vivo of expanded Treg cells prevents diabetes development in prediabetic mice and stably reverse diabetes in mice with recent disease onset.…”

Section: Act Of Treg Cells For Autoimmune Diseasesmentioning

confidence: 99%

“…[100][101][102][103][104][105][106] Alternately, tissue antigen-specific TCRs could be identified by using single-cell TCR sequencing and used to redirect Treg cell specificity. 62,107 Several groups have inserted TCRs specific for insulin and glutamate decarboxylase into human Treg cells, which enables antigen-specific suppression. 108,109 At this stage, it remains unclear whether repurposed TCRs derived from effector T cells have the same biological function as TCRs from Treg cells.…”

Section: Current Challenges and Future Prospects Of Treg Cell Therapymentioning

confidence: 99%

See 1 more Smart Citation

Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier

Esensten

Müller

Bluestone

et al. 2018

Journal of Allergy and Clinical Immunology

Self Cite

138

104

View full text Add to dashboard Cite

Forkhead box P3-expressing regulatory T (Treg) cells are essential for self-tolerance, with an emerging role in tissue repair and regeneration. Their ability to traffic to tissue and perform complex therapeutic tasks in response to the tissue microenvironment make them an attractive candidate for drug development. Early experiences of Treg cell therapy in patients with graft-versus-host disease, type 1 diabetes, and organ transplantation have shown that it is feasible, safe, and potentially efficacious in some settings. Many ongoing trials in patients with a wide variety of diseases will further enhance our knowledge about the optimal approaches for Treg cell manufacturing and dosing. We review the current preclinical rationale supporting Treg cell therapy in a variety of disease settings ranging from tissue transplantation, autoimmune diseases, and non-immunemediated inflammatory settings. We point out challenges in development of Treg cell therapy and speculate how synthetic biology can be used to enhance the feasibility and efficacy of Treg cell therapy for autoimmune and autoinflammatory diseases. (J

show abstract

Section: Act Of Treg Cells For Autoimmune Diseasesmentioning

confidence: 99%

Section: Current Challenges and Future Prospects Of Treg Cell Therapymentioning

confidence: 99%

Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier

Esensten

Müller

Bluestone

et al. 2018

Journal of Allergy and Clinical Immunology

Self Cite

138

104

View full text Add to dashboard Cite

show abstract

“…However, autologous Islet transplant recipients exhibit a slow loss of insulin independence despite absence of allogeneic and autoimmunity [103][104][105] revealing a significant contribution of nonimmune factors in long-term graft dysfunction that must be identified and controlled. To combine other cellular therapies with Islet transplantation, such as the use of autologous or allogeneic mesenchymal stem cells (MSCs) or Tregs, are innovative strategies that could support islet health, revascularization, and induce immune tolerance 106,107 . Close collaborations with the sharing of findings and increased participation in registries are warranted to improve standard clinical practice and obtain proper reimbursement from health authorities worldwide.…”

Section: A C C E P T E Dmentioning

confidence: 99%

β Cell Replacement Therapy

et al. 2018

View full text Add to dashboard Cite

β cell replacement with either pancreas or islet transplantation has progressed immensely over the last decades with current 1- and 5-year insulin independence rates of approximately 85% and 50%, respectively. Recent advances are largely attributed to improvements in immunosuppressive regimen, donor selection, and surgical technique. However, both strategies are compromised by a scarce donor source. Xenotransplantation offers a potential solution by providing a theoretically unlimited supply of islets, but clinical application has been limited by concerns for a potent immune response against xenogeneic tissue. β cell clusters derived from embryonic or induced pluripotent stem cells represent another promising unlimited source of insulin producing cells, but clinical application is pending further advances in the function of the β cell like clusters. Exciting developments and rapid progress in all areas of β cell replacement prompted a lively debate by members of the young investigator committee of the International Pancreas and Islet Transplant Association at the 15th International Pancreas and Islet Transplant Association Congress in Melbourne and at the 26th international congress of The Transplant Society in Hong Kong. This international group of young investigators debated which modality of β cell replacement would predominate the landscape in 10 years, and their arguments are summarized here.

show abstract

“…These results indicate that polyherbal extract could stimulate the production of Treg cells. Regarding the important role of Tregs in T1D, boosting Tregs number may provide an effective aspect of diabetes treatment [36,37].…”

Section: Effect Of Polyherbal Administration On Relative Amount Of Rementioning

confidence: 99%

Anti-hyperglycemic and Immunomodulatory Activity of a Polyherbal Composed of Sesbania grandiflora, Salacca zalacca and Acalypha indica

Zamroni¹,

Zubaidah

Rifa’i

et al. 2018

JELS

View full text Add to dashboard Cite

Diabetes has become a serious global public health problem due to its high prevalence and mortality. Unfortunately, current anti-diabetic drugs are having some limitations and adverse effects. Therefore, searching for a new anti-diabetic agent is an urgent challenge. In this research, we examined the effectiveness of a traditional anti-diabetic polyherbal composed of Sesbania grandiflora seeds, Salacca zalacca leaves and Acalypha indica roots (2:1:1). The study was aimed to explore the anti-hyperglycemic effect of the polyherbal in STZ-induced diabetic mice and to investigate the immunomodulatory activity involved in the process of controlling hyperglycemia. Our results showed that the polyherbal water extract (150 mg.kgBW-1) could suppress blood glucose elevation and preserve pancreatic islet of diabetic mice. Moreover, the polyherbal treatment could normalize the relative amount of activated CD4 + CD62Land CD8 + CD62L-T cells. The polyherbal extract also stimulated the production of CD4 + CD25 + FoxP3 + regulatory T cells (Tregs) which is known to play an important role in diabetes control. In addition, polyherbal treatment also increased the relative amount of anti-inflammatory cytokines IL-10 and TGF-β. These results revealed that the polyherbal extract has an anti-hyperglycemic and immunomodulatory activity that may provide beneficial function in diabetes healing.

show abstract

Restoring Regulatory T Cells in Type 1 Diabetes

Abstract: Keywords Regulatory T cells (Tregs)Type

Cited by 32 publications

References 129 publications

Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier

Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier

β Cell Replacement Therapy

Anti-hyperglycemic and Immunomodulatory Activity of a Polyherbal Composed of Sesbania grandiflora, Salacca zalacca and Acalypha indica

Contact Info

Product

Resources

About